Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin.

Delattre IK, Musuamba FT, Verbeeck RK, Dugernier T, Spapen H, Laterre PF, Wittebole X, Cumps J, Taccone FS, Vincent JL, Jacobs F, Wallemacq PE.

Clin Biochem. 2010 Apr;43(6):589-98. doi: 10.1016/j.clinbiochem.2009.12.007. Epub 2009 Dec 28.

PMID:
20036226
2.

Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin.

Delattre IK, Musuamba FT, Jacqmin P, Taccone FS, Laterre PF, Verbeeck RK, Jacobs F, Wallemacq P.

Clin Biochem. 2012 Jul;45(10-11):780-6. doi: 10.1016/j.clinbiochem.2012.03.030. Epub 2012 Apr 5.

PMID:
22503878
3.

Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.

Delattre IK, Musuamba FT, Nyberg J, Taccone FS, Laterre PF, Verbeeck RK, Jacobs F, Wallemacq PE.

Ther Drug Monit. 2010 Dec;32(6):749-56. doi: 10.1097/FTD.0b013e3181f675c2.

PMID:
20962708
4.

Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.

Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F.

Crit Care. 2010;14(4):R126. doi: 10.1186/cc9091. Epub 2010 Jul 1.

5.

Case-control study of drug monitoring of β-lactams in obese critically ill patients.

Hites M, Taccone FS, Wolff F, Cotton F, Beumier M, De Backer D, Roisin S, Lorent S, Surin R, Seyler L, Vincent JL, Jacobs F.

Antimicrob Agents Chemother. 2013 Feb;57(2):708-15. doi: 10.1128/AAC.01083-12. Epub 2012 Nov 12.

6.

Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.

Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J.

Int J Antimicrob Agents. 2010 Oct;36(4):332-9. doi: 10.1016/j.ijantimicag.2010.06.008. Epub 2010 Aug 3.

PMID:
20685085
7.

Can changes in renal function predict variations in β-lactam concentrations in septic patients?

Casu GS, Hites M, Jacobs F, Cotton F, Wolff F, Beumier M, De Backer D, Vincent JL, Taccone FS.

Int J Antimicrob Agents. 2013 Nov;42(5):422-8. doi: 10.1016/j.ijantimicag.2013.06.021. Epub 2013 Aug 11.

PMID:
23993066
8.

Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.

Mar Fernández de Gatta MD, Victoria Calvo M, Ardanuy R, Domínguez-Gil A, Lanao JM, Moreno SR.

J Pharm Pharmacol. 2009 Jun;61(6):759-66. doi: 10.1211/jpp/61.06.0008.

PMID:
19505366
9.

Rapid quantification of six β-lactams to optimize dosage regimens in severely septic patients.

Wolff F, Deprez G, Seyler L, Taccone F, Hites M, Gulbis B, Vincent JL, Jacobs F, Cotton F.

Talanta. 2013 Jan 15;103:153-60. doi: 10.1016/j.talanta.2012.10.024. Epub 2012 Oct 18.

PMID:
23200371
10.

Therapeutic drug monitoring of amikacin in septic patients.

Duszynska W, Taccone FS, Hurkacz M, Kowalska-Krochmal B, Wiela-Hojeńska A, Kübler A.

Crit Care. 2013 Jul 25;17(4):R165. doi: 10.1186/cc12844.

11.
12.

Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?

Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J.

Crit Care Med. 2009 Mar;37(3):926-33. doi: 10.1097/CCM.0b013e3181968e44.

PMID:
19237898
13.

β-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia.

Hayashi Y, Lipman J, Udy AA, Ng M, McWhinney B, Ungerer J, Lust K, Roberts JA.

Int J Antimicrob Agents. 2013 Feb;41(2):162-6. doi: 10.1016/j.ijantimicag.2012.10.002. Epub 2012 Nov 13.

PMID:
23153962
14.

Even high-dose extended infusions may not yield desired concentrations of β-lactams: the value of therapeutic drug monitoring.

Cotta MO, Gowen B, Truloff N, Bursle E, McWhinney B, Ungerer JP, Roberts JA, Lipman J.

Infect Dis (Lond). 2015;47(10):739-42. doi: 10.3109/23744235.2015.1021831. Epub 2015 Mar 10.

PMID:
25753768
15.

The ANTIBIOPERF study: a nationwide cross-sectional survey about practices for β-lactam administration and therapeutic drug monitoring among critically ill patients in France.

Charmillon A, Novy E, Agrinier N, Leone M, Kimmoun A, Levy B, Demoré B, Dellamonica J, Pulcini C.

Clin Microbiol Infect. 2016 Jul;22(7):625-31. doi: 10.1016/j.cmi.2016.04.019. Epub 2016 May 1.

16.

β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review.

Sinnollareddy MG, Roberts MS, Lipman J, Roberts JA.

Clin Exp Pharmacol Physiol. 2012 Jun;39(6):489-96. doi: 10.1111/j.1440-1681.2012.05715.x. Review.

PMID:
22519600
17.

Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.

Mahmoudi L, Mohammadpour AH, Ahmadi A, Niknam R, Mojtahedzadeh M.

Eur Rev Med Pharmacol Sci. 2013 Feb;17(3):285-91.

18.

An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units.

Wong G, Brinkman A, Benefield RJ, Carlier M, De Waele JJ, El Helali N, Frey O, Harbarth S, Huttner A, McWhinney B, Misset B, Pea F, Preisenberger J, Roberts MS, Robertson TA, Roehr A, Sime FB, Taccone FS, Ungerer JP, Lipman J, Roberts JA.

J Antimicrob Chemother. 2014 May;69(5):1416-23. doi: 10.1093/jac/dkt523. Epub 2014 Jan 16.

PMID:
24443514
19.

Therapeutic drug monitoring of vancomycin in severe sepsis and septic shock.

Vázquez M, Fagiolino P, Boronat A, Buroni M, Maldonado C.

Int J Clin Pharmacol Ther. 2008 Mar;46(3):140-5.

PMID:
18397685
20.

Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity.

Gálvez R, Luengo C, Cornejo R, Kosche J, Romero C, Tobar E, Illanes V, Llanos O, Castro J.

Int J Antimicrob Agents. 2011 Aug;38(2):146-51. doi: 10.1016/j.ijantimicag.2011.03.022. Epub 2011 May 25.

PMID:
21612894

Supplemental Content

Support Center